Analysts Anticipate NuCana PLC (NCNA) to Announce -$0.26 EPS

Share on StockTwits

Equities analysts expect NuCana PLC (NASDAQ:NCNA) to report earnings of ($0.26) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for NuCana’s earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.28). The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.

Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for NuCana.

NuCana (NASDAQ:NCNA) last posted its quarterly earnings results on Tuesday, August 28th. The company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.19.

A number of equities research analysts recently weighed in on NCNA shares. Cowen reissued a “buy” rating on shares of NuCana in a research note on Wednesday, August 29th. Zacks Investment Research raised shares of NuCana from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Thursday, October 4th. Finally, ValuEngine raised shares of NuCana from a “hold” rating to a “buy” rating in a research note on Tuesday, October 2nd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $24.33.

Large investors have recently modified their holdings of the business. Alps Advisors Inc. increased its stake in NuCana by 8.2% in the second quarter. Alps Advisors Inc. now owns 46,269 shares of the company’s stock valued at $879,000 after purchasing an additional 3,508 shares in the last quarter. Asymmetry Capital Management L.P. increased its stake in NuCana by 18.4% in the second quarter. Asymmetry Capital Management L.P. now owns 47,872 shares of the company’s stock valued at $910,000 after purchasing an additional 7,424 shares in the last quarter. Woodford Investment Management Ltd increased its stake in NuCana by 27.3% in the second quarter. Woodford Investment Management Ltd now owns 420,000 shares of the company’s stock valued at $7,980,000 after purchasing an additional 90,000 shares in the last quarter. Baillie Gifford & Co. increased its stake in NuCana by 2.2% in the second quarter. Baillie Gifford & Co. now owns 655,450 shares of the company’s stock valued at $12,454,000 after purchasing an additional 14,330 shares in the last quarter. Finally, Sofinnova Ventures Inc bought a new stake in NuCana in the first quarter valued at approximately $88,293,000. 24.42% of the stock is owned by hedge funds and other institutional investors.

Shares of NCNA traded down $0.80 on Friday, reaching $17.53. 38,583 shares of the company’s stock were exchanged, compared to its average volume of 79,774. The company has a market cap of $792.73 million and a price-to-earnings ratio of -16.54. NuCana has a 12 month low of $9.32 and a 12 month high of $32.00.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.

See Also: How to Invest in the Dividend Aristocrat Index

Get a free copy of the Zacks research report on NuCana (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NuCana (NASDAQ:NCNA)

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply